Disruption of metal transport proteins can lead to both toxic accumulation and essential deficiencies (Zheng and Monnot, 2012).Chelation therapies and metal modulating nutraceuticals are currently under investigation as potential therapeutic options in AD (Sensi et al., 2018)
J Pharmacol Exp Ther 251:216223 [PubMed] [Google Scholar] Stockton SD, Jr, Devi LA
The analysis of polymorphisms in GST genes confirmed that mutations lead to weaker antioxidant barriers and may contribute to the development of AMD
This can be achieved using antiangiogenic agents which promote vascular normalization [28, 29]
Paradoxically, the resultant abnormal vasculature exacerbates hypoxic conditions and creates a vicious cycle, wherein the progressively abnormal TME continues to foster angiogenesis and hypoxia in tumors
Table 2 Comparison of medicinal values of main parts